Gleevec (imatinib) for a certain kind of stomach cancer
October 2002
Novartis is now promoting Gleevec (imatinib) for a certain kind of stomach cancer.
Gleevec hit the market last year for chronic myeloid leukemia.
Now it's approved for gastrointestinal stromal tumours (GIST). These tumours are rare...but HIGHLY resistant to conventional chemo.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote